Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
Table 1
Clinicopathological features.
Patient ID
Age at surgery
Pathological stage
Margin status
Gleason score1
Other pathological features
PSA level (preoperative or pre-ADT)
PSA levels after surgery
PSA recurrence
PSA at last follow-up2
Did not receive neoadjuvant androgen-deprivation therapy:
#01
62
T3b
+
7
EPE, SV
55.61
0.14
Yes
1.7
#02
51
T2c
−
6
PNI
7.13
<0.05
No
<0.05
#03
65
T1c
+
7
PNI
6.13
<0.05
Yes
0.037
#04
64
T2c
−
6
PNI
5.25
<0.05
No
<0.05
#05
62
T2
−
7
EPE, PNI
3.16
<0.05
No
<0.05
#06
62
T2
−
7
PNI
6.26
<0.05
No
<0.05
#07
66
T2
−
7
Nil
17.6
<0.04
No
<0.05
#08
69
T3b
−
7
PNI, EPE, SV
24.64
0.27
No
0.24
#09
64
T3a
−
7
PNI, EPE
10.07
<0.05
Yes
0.12
#10
50
T3a
+
7
PNI
45.28
0.056
Yes
<0.05
Received neoadjuvant androgen-deprivation therapy:
#11
59
T2c
−
n/a
NiI
5.38
<0.05
No
<0.05
#12
69
T2c
−
n/a
PNI
13.84
<0.05
Yes
0.14
#13
62
T2c
−
n/a
PNI
10.19
<0.05
No
<0.05
#14
49
T3a
−
n/a
PNI
247.4
0.08
Yes
0.08
#15
67
T3b
+
n/a
PNI, EPE, SV (bilat)
33.88
<0.05
Yes
<0.05
ADT, androgen-deprivation therapy; EPE, extraprostatic extension; PNI, perineural invasion; PSA, prostate-specific antigen; SVI, seminal vesicle involvement. Only malignant tissue was available; that is, matched nonmalignant tissue was not assessed. 1Gleason score not assessed (n/a) in those treated with neoadjuvant androgen-deprivation therapy. 2Median time to follow-up after surgery was 887 days.
